Login / Signup

Responsiveness of outcome measures in myotonic dystrophy type 1.

Kirsten L KnakAisha M SheikhNanna WittingJohn Vissing
Published in: Annals of clinical and translational neurology (2020)
Overall, adequate responsiveness was shown for both muscle strength dynamometers, TUG and mCTSIB. These outcomes are therefore likely candidate endpoints for clinical trials lasting 1 year. Most static balance tests are not responsive and not recommended in a heterogeneous DM1 population.
Keyphrases
  • clinical trial
  • early onset
  • cancer therapy
  • muscular dystrophy
  • phase ii
  • metabolic syndrome
  • drug delivery
  • study protocol
  • adipose tissue
  • double blind